Micardis telmisartan/hydrochlorothiazide: Phase IV data

The double-blind, international Phase IV PRoFESS trial in 20,332 stroke patients showed that 80 mg telmisartan once daily missed the primary endpoint of a significant reduction in the rate of recurren...